Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2026-04-15 Proxy Solicitation & In…
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026 - Attachment: Navamedic ASA - Recommendations by the Nomination Committee 2026.pdf
Proxy Solicitation & Information Statement Classification · 90% confidence The document consists of recommendations by the Nomination Committee in advance of the upcoming General Meeting, including proposed board elections, committee appointments, and director remuneration. It is clearly designed to inform shareholders and solicit their votes at the AGM. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials to shareholders to request votes for meeting proposals.
2026-04-15 English
Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a stock exchange announcement of the nomination committee’s recommendations for board and committee candidates ahead of the Annual General Meeting, including information on proposed remuneration and a link to the full materials. This is clearly part of the proxy materials sent to shareholders to inform and solicit votes (i.e., proxy solicitation & information statement).
2026-04-15 English
Navamedic ASA: Notice of Annual General Meeting - Attachment: Navamedic ASA - Notice of AGM 23 April 2026.pdf
Proxy Solicitation & Information Statement Classification · 90% confidence The document is the formal notice (“Innkalling”) and information statement for Navamedic ASA’s 2026 Annual General Meeting. It lists agenda items, board and committee elections, approval of accounts, dividend authorisation, remuneration reports, capital authorisations, and instructions on attending, voting in advance, or by proxy. This matches the definition of a proxy solicitation & information statement (materials sent to shareholders to provide information and request votes for a meeting). It is not the AGM presentation itself, not a full annual report, but the pre-meeting information and vote solicitation document.
2026-03-31 Norwegian
Navamedic ASA: Notice of Annual General Meeting
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice announcing the date, time, location, and related materials (agenda, proxy forms, advance voting instructions) for the company’s upcoming Annual General Meeting. This is exactly the type of information sent to shareholders to provide details and request their votes on agenda items. Under our taxonomy, materials sent to shareholders to request votes (including proxy forms and meeting agendas) are classified as a Proxy Solicitation & Information Statement (PSI).
2026-03-31 English
Annual Report 2025 - Attachment: Navamedic ASA Annual Report 2025.pdf
Annual Report Classification · 100% confidence The document is titled 'Annual report 2025' and contains comprehensive sections including highlights, key figures, a message from the CEO, a directors' report, consolidated financial statements, notes to the financial statements, and an independent auditor's report. It covers the full fiscal year 2025 and provides detailed financial performance data, which aligns with the definition of an Annual Report (10-K). FY 2025
2026-03-25 English
Annual Report 2025 - Attachment: NavamedicASA-2025-12-31-1-en.zip
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-03-25 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.